The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Neoantigen-directed immune escape in lung cancer evolution
Open accessAbstract
The interplay between an evolving cancer and a dynamic immune microenvironment remains unclear. Here we analyse 258 regions from 88 early-stage, untreated non-small-cell lung cancers using RNA sequencing and histopathology-assessed tumour-infiltrating lymphocyte estimates. Immune infiltration varied both between and within tumours, with different mechanisms of neoantigen presentation dysfunction enriched in distinct immune microenvironments. Sparsely infiltrated tumours exhibited a waning of neoantigen editing during tumour evolution, indicative of historical immune editing, or copy-number loss of previously clonal neoantigens. Immune-infiltrated tumour regions exhibited ongoing immunoediting, with either loss of heterozygosity in human leukocyte antigens or depletion of expressed neoantigens. We identified promoter hypermethylation of genes that contain neoantigenic mutations as an epigenetic mechanism of immunoediting. Our results suggest that the immune microenvironment exerts a strong selection pressure in early-stage, untreated non-small-cell lung cancers that produces multiple routes to immune evasion, which are clinically relevant and forecast poor disease-free survival.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Various mechanisms of immune evasion present in early-stage untreated cancers could impose selection pressure on the evolving tumors through affecting neoantigens and antigen presentation”
From Hallmarks of response, resistance, and toxicity to immune checkpoint blockade (2021) · cites this paper as Rosenthal et al., 2019
Experimental — accuracy not yet measuredIn the citing paper
“clonal diversities of different tumor regions in lung adenocarcinomas were negatively correlated with CD8+ T cell infiltration within those regions”
From Hallmarks of response, resistance, and toxicity to immune checkpoint blockade (2021) · cites this paper as Rosenthal et al., 2019
In the citing paper
“Evolving tumor subclones with disruption in antigen presentation or neoantigen depletion at DNA and RNA levels were subject to positive selection”
From Hallmarks of response, resistance, and toxicity to immune checkpoint blockade (2021) · cites this paper as Rosenthal et al., 2019
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
STAR: ultrafast universal RNA-seq aligner
Dobin, A., Davis, C. A., Schlesinger, F., Drenkow, J., Zaleski, C., Jha, S., Batut, P., Chaisson, M., & Gingeras, T. R. (2013) · Bioinformatics · doi:10.1093/bioinformatics/bts635 · Cited by 51,709
Cutadapt removes adapter sequences from high-throughput sequencing reads
Martin, M. (2011) · EMBnet.journal · doi:10.14806/ej.17.1.200 · Cited by 33,889
RSEM: accurate transcript quantification from RNA-Seq data with or without a reference genome
Li, B., & Dewey, C. N. (2011) · BMC Bioinformatics · doi:10.1186/1471-2105-12-323 · Cited by 22,179
Robust enumeration of cell subsets from tissue expression profiles
Newman, A. M., Liu, C. L., Green, M. R., Gentles, A. J., Feng, W., Xu, Y., Hoang, C. D., Diehn, M., & Alizadeh, A. A. (2015) · Nature Methods · doi:10.1038/nmeth.3337 · Cited by 13,224
Type, Density, and Location of Immune Cells Within Human Colorectal Tumors Predict Clinical Outcome
Galon, J., Costes, A., Sanchez-Cabo, F., Kirilovsky, A., Mlecnik, B., Lagorce-Pagès, C., Tosolini, M., Camus, M., Berger, A., Wind, P., et al. (2006) · Science · doi:10.1126/science.1129139 · Cited by 6,516
Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response
Jiang, P., Gu, S., Pan, D., Fu, J., Sahu, A., Hu, X., Li, Z., Traugh, N., Bu, X., Li, B., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0136-1 · Cited by 5,179
Charoentong, P., Finotello, F., Angelova, M., Mayer, C., Efremova, M., Rieder, D., Hackl, H., & Trajanoski, Z. (2017) · Cell Reports · doi:10.1016/j.celrep.2016.12.019 · Cited by 5,041
xCell: digitally portraying the tissue cellular heterogeneity landscape
Aran, D., Hu, Z., & Butte, A. J. (2017) · Genome Biology · doi:10.1186/s13059-017-1349-1 · Cited by 4,397
Molecular and genetic properties of tumors associated with local immune cytolytic activity
Rooney, M. S., Shukla, S. A., Wu, C. J., Getz, G., & Hacohen, N. (2015) · Cell · doi:10.1016/j.cell.2014.12.033 · Cited by 3,825
IFN-γ–related mRNA profile predicts clinical response to PD-1 blockade
Ayers, M., Lunceford, J., Nebozhyn, M., Murphy, E., Loboda, A., Kaufman, D. R., Albright, A., Cheng, J. D., Kang, S. P., Shankaran, V., et al. (2017) · Journal of Clinical Investigation · doi:10.1172/jci91190 · Cited by 3,788
Cited by
Inflammation and cancer: triggers, mechanisms, and consequences
Greten, F. R., & Grivennikov, S. I. (2019) · Immunity · doi:10.1016/j.immuni.2019.06.025 · Cited by 3,806
Top 10 Challenges in Cancer Immunotherapy
Hegde, P. S., & Chen, D. S. (2020) · Immunity · doi:10.1016/j.immuni.2019.12.011 · Cited by 2,238
Immunotherapies for hepatocellular carcinoma
Llovet, J. M., Castet, F., Heikenwalder, M., Maini, M. K., Mazzaferro, V., Pinato, D. J., Pikarsky, E., Zhu, A. X., & Finn, R. S. (2022) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00573-2 · Cited by 1,843
Hallmarks of response, resistance, and toxicity to immune checkpoint blockade
Morad, G., Helmink, B. A., Sharma, P., & Wargo, J. A. (2021) · Cell · doi:10.1016/j.cell.2021.09.020 · Cited by 1,648
PD-L1 as a biomarker of response to immune-checkpoint inhibitors
Doroshow, D. B., Bhalla, S., Beasley, M. B., Sholl, L. M., Kerr, K. M., Gnjatic, S., Wistuba, I. I., Rimm, D. L., Tsao, M. S., & Hirsch, F. R. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00473-5 · Cited by 1,575
Metadata
- Authors
- The TRACERx consortium, Rosenthal, R., Cadieux, E. L., Salgado, R., Bakir, M. A., Moore, D. A., Hiley, C. T., Lund, T., Tanić, M., Reading, J. L., Joshi, K., Henry, J. Y., Ghorani, E., Wilson, G. A., Birkbak, N. J., Jamal-Hanjani, M., Veeriah, S., Szallasi, Z., Loi, S., Hellmann, M. D., Feber, A., Chain, B., Herrero, J., Quezada, S. A., Demeulemeester, J., Van Loo, P., Beck, S., McGranahan, N., & Swanton, C.
- Affiliations
- The Francis Crick Institute (GB)
- The University of Melbourne (AU)
- University College London (GB)
- Cancer Research UK (GB)
- Memorial Sloan Kettering Cancer Center (US)
- Corresponding author
- McGranahan, Nicholas
- Swanton, Charles
- ORCID
- Rosenthal, Rachel
- Cadieux, Elizabeth Larose
- Bakir, Maise Al
- Moore, David A.
- Hiley, Crispin T.
- Lund, Tom
- Tanić, Miljana
- Reading, James L.
- Henry, Jake Y.
- Ghorani, Ehsan
- Wilson, Gareth A.
- Birkbak, Nicolai J.
- Veeriah, Selvaraju
- Loi, Sherene
- Hellmann, Matthew D.
- Feber, Andrew
- Chain, Benny
- Herrero, Javier
- Quezada, Sergio A.
- Demeulemeester, Jonas
- Beck, Stephan
- McGranahan, Nicholas
- Swanton, Charles
- Venue
- Nature
- Published
- 2019-03
- Volume
- 567
- Issue
- 7749
- Pages
- 479-485
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC6954100
- OpenAlex
- W2924359886
- Cited by
- 946
- References
- 35
- Citations by year
- 2026: 81 · 2025: 95 · 2024: 117 · 2023: 139 · 2022: 152 · 2021: 178 · 2020: 117 · 2019: 66
- FWCI
- 54.65
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- Research Explorer (The University of Manchester) (publishedVersion)
- PubMed Central (acceptedVersion)
- White Rose Research Online (University of Leeds, The University of Sheffield, University of York) (acceptedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- ENLIGHTEN (Jurnal Bimbingan dan Konseling Islam) (submittedVersion, cc-by-sa)
- UCL Discovery (University College London) (submittedVersion)
- Figshare (submittedVersion, cc-by)
- Lirias (KU Leuven) (submittedVersion)
- Funders
- Wellcome Trust (FC001202, FC001169, 107963/Z/15/Z, 211179/Z/18/Z)
- Francis Crick Institute (10169, 10002, 10233, 10202)
- Cancer Research UK (19278, 23896, 24314, 20466, A22246, A20764, 16463, 24956, 20764, S_3441, 21999, 28990, 17786, 22246, 20265, 29420, 20465, 29569, 30025)
- National Institute for Health and Care Research (CL-2015-17-002, CL-2015-18-009, ACF-2014-18-006)
- Royal Society
- Rosetrees Trust
- Novo Nordisk Fonden (NNF15OC0016584)
- National Cancer Institute (P30CA008748)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- neoantigens, immune evasion, non-small cell lung cancer, tumor immune microenvironment, tumor-infiltrating lymphocytes, immunoediting, loss of heterozygosity, HLA loss, copy number loss, promoter hypermethylation, tumor evolution, disease-free survival
- MeSH terms
- Adenocarcinoma, Antigens, Neoplasm, Carcinoma, Non-Small-Cell Lung, Carcinoma, Squamous Cell, Female, Humans, Lung Neoplasms, Male, Prognosis, Gene Expression Regulation, Neoplastic, Lymphocytes, Tumor-Infiltrating, Antigen Presentation, Disease-Free Survival, Tumor Escape, Evolution, Molecular, Tumor Microenvironment
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Neoantigen-directed immune escape in lung cancer evolution. https://app.cochat.ai/papers/10.1038/s41586-019-1032-7
- The paper
- The TRACERx consortium, Rosenthal, R., Cadieux, E. L., Salgado, R., Bakir, M. A., Moore, D. A., Hiley, C. T., Lund, T., Tanić, M., Reading, J. L., Joshi, K., Henry, J. Y., Ghorani, E., Wilson, G. A., Birkbak, N. J., Jamal-Hanjani, M., Veeriah, S., Szallasi, Z., Loi, S., . . . Swanton, C. (2019). Neoantigen-directed immune escape in lung cancer evolution. Nature. https://doi.org/10.1038/s41586-019-1032-7
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.